Table 3 Analysis of olopatadine hydrochloride in pharmaceutical products
Concentration of quality control samples (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Batch | Raw material (μg/mL) | Tablet (μg/mL) | Eye drop (μg/mL) | ||||||
5 | 10 | 15 | 5 | 10 | 15 | 5 | 10 | 15 | |
A | 100.23 | 100.92 | 99.83 | 99.93 | 99.99 | 100.19 | 100.83 | 99.48 | 100.03 |
B | 101.02 | 99.28 | 100.12 | 98.99 | 99.63 | 99.92 | 100.41 | 100.69 | 100.28 |
C | 99.36 | 100.04 | 99.94 | 100.29 | 100.59 | 100.46 | 99.98 | 100.83 | 99.56 |
D | 98.94 | 100.91 | 100.46 | 100.06 | 100.48 | 100.56 | 99.74 | 99.93 | 99.09 |
E | 100.32 | 99.76 | 99.83 | 99.89 | 99.67 | 99.89 | 100.46 | 100.91 | 100.06 |
F | 100.19 | 99.89 | 100.11 | 100.56 | 100.16 | 100.15 | 100.29 | 100.02 | 100.04 |
Mean | 100.01 | 100.13 | 100.05 | 99.95 | 100.09 | 100.20 | 100.29 | 100.31 | 99.84 |
SD | 0.556 | 0.404 | 0.498 | ||||||